Determinants of survival of extremely low birth weight infants in a rural Nigerian Hospital

Background: Over 90% of the neonatal deaths occur in low- and middle-income countries, mostly in sub-Saharan Africa, includingNigeria. Prematurity is related to more than one-third of these deaths on a global scale; with the extremely low birth weight (ELBW)category having a 100-fold mortality risk compared to the normal birth weight infants. Objective: The purpose of this study wasto determine the survival rates of ELBW infants and to identify the factors associated with survival in a rural hospital in Nigeria.Materials and Methods: All the neonates admitted to the unit weighing <1000 g at admission were enrolled. The birth place,gender, gestational age (GA), birth weight, postnatal age, temperature, blood sugar at admission, and outcome were documented.None of the babies received surfactant or assisted ventilation. Results: 29 out of 992 neonates (3%) admitted to the neonatalunit over the study period were ELBW. The survival rates of the inborn and outborn neonates were 33% and 14%, respectively.Conclusions: Factors associated with increased survival were inborn, GA ≥28 weeks, birth weight of 750 g, inborn and admissionwithin 2 h of life

Blood pressure control and left ventricular hypertrophy in hypertensive Nigerians

Background : Hypertension is a disease characterized by end-organ complications, leading to high morbidity and mortality in many cases. People with untreated or uncontrolled hypertension often run the risk of developing complications directly associated with the disease. Left ventricular hypertrophy (LVH) has been shown to be a significant risk factor for adverse outcomes both in patients with hypertension and in the general population. We investigated the prevalence and pattern of LVH in a treated hypertensive population at the University College Hospital, Ibadan, Nigeria, using non-hypertensive subjects as control. Design and Setting : A prospective observational study performed at the University College Hospital, Ibadan, Nigeria. Methods : Patients had 6 visits, when at least one blood pressure measurement was recorded for each hypertensive subject and average calculated for systolic blood pressure (SBP) and diastolic blood pressure (DBP) separately. The values obtained were used for stratification of the subjects into controlled and uncontrolled hypertension. Subjects also had echocardiograms to determine their left ventricular mass. Results : LVH was found in 14 (18.2%) of the normotensive group, 40 (20.8%) of the uncontrolled hypertensive group and 14 (24.1%) of the controlled hypertensive group when left ventricular mass (LVM) was indexed to body surface area (BSA). When LVM was indexed to height, left ventricular hypertrophy was found in none of the subjects of the normotensive group, while it was found present in 43 (22.4%) and 14 (24.1%) subjects of the uncontrolled and controlled hypertensive groups, respectively. Significant difference in the prevalence of LVH was detected only when LVM was indexed to height alone. Conclusion : Clinic blood pressure is an ineffective way of assessing BP control. Thus in apparently controlled hypertensive subjects, based on office blood pressure, cardiac structural changes do remain despite antihypertensive therapy. This population is still at risk of cardiovascular events.arri\ue8re-plan: l\u2019hypertension est une maladie caract\ue9ris\ue9e par l\u2019orgue de fi n complications menant \ue0 \ue9lev\ue9 de morbidit\ue9 et mortalit\ue9 dans de nombreux cas. Personnes avec l\u2019hypertension non trait\ue9e ou non contr\uf4l\ue9e souvent risquent de d\ue9velopper complications directement associ\ue9es \ue0 la maladie. Laiss\ue9 ventriculaire hypertrophie (LVH) a \ue9t\ue9 d\ue9montr\ue9 un facteur de risque signifi catif pour les effets n\ue9gatifs r\ue9sultats tant chez les patients atteints de l\u2019hypertension et de la population g\ue9n\ue9rale. Nous avons a enqu\ueat\ue9 sur la pr\ue9valence et le mod\ue8le de LVH dans un trait\ue9 hypertendues population au University College Hospital, \ue0 l\u2019aide Ibadan, Nigeria non-hypertendues des sujets comme contr\uf4le. conception et la confi guration: A \ue9ventuel \ue9tude d\u2019observation effectu\ue9e \ue0 la University College Hospital, Ibadan, Nigeria. m\ue9thodes: Patients avaient six visites o\uf9 au moins un sang mesure de pression a \ue9t\ue9 enregistr\ue9e pour chaque sujet hypertendues et moyenne calcul\ue9s s\ue9par\ue9ment pour SBP et DBP. Les valeurs obtenues ont \ue9t\ue9 utilis\ue9es pour stratifi cation des sujets dans l\u2019hypertension contr\uf4l\ue9e et incontr\uf4l\ue9e. Sujets ont \ue9galement echocardiograms pour d\ue9terminer leur masse ventriculaire gauche. r\ue9sultats: LVH a \ue9t\ue9 trouv\ue9 en 14(18.2%) de la groupe normotensive, 40(20.8%) de groupe de hypertendues non contr\uf4l\ue9es et 14(24.1%) de hypertendues contr\uf4l\ue9e groupe lorsque quitt\ue9 masse ventriculaire (LVM) a \ue9t\ue9 index\ue9e \ue0 corps surface (BSA). Lorsque LVM a \ue9t\ue9 index\ue9 \ue0 hauteur, laiss\ue9 ventriculaire hypertrophie a \ue9t\ue9 trouv\ue9 dans aucun du groupe normotensive, bien qu\u2019il a \ue9t\ue9 constat\ue9 pr\ue9sents dans les 43(22.4%) et 14(24.1%) de hypertendues non ma\ueetris\ue9e et contr\uf4l\ue9e groupes respectivement. \uc9tait de diff\ue9rence signifi cative dans la pr\ue9valence de la LVH d\ue9tect\ue9s uniquement lorsque LVM a \ue9t\ue9 index\ue9 \ue0 hauteur alone. conclusion: clinique art\ue9rielle est un moyen ineffi cace de mesurer le contr\uf4le de BP. Ainsi en sujet hypertendues apparemment contr\uf4l\ue9e bas\ue9e sur la pression art\ue9rielle de bureau, des changements structurels cardiaques restent malgr\ue9 th\ue9rapie antihypertensive. Cette population est toujours \ue0 risque de maladies cardiovasculaires \ue9v\ue9nements

Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis

BACKGROUND: Rates of antimicrobial resistance (AMR) are rising globally and there is concern that increased migration is contributing to the burden of antibiotic resistance in Europe. However, the effect of migration on the burden of AMR in Europe has not yet been comprehensively examined. Therefore, we did a systematic review and meta-analysis to identify and synthesise data for AMR carriage or infection in migrants to Europe to examine differences in patterns of AMR across migrant groups and in different settings. METHODS: For this systematic review and meta-analysis, we searched MEDLINE, Embase, PubMed, and Scopus with no language restrictions from Jan 1, 2000, to Jan 18, 2017, for primary data from observational studies reporting antibacterial resistance in common bacterial pathogens among migrants to 21 European Union-15 and European Economic Area countries. To be eligible for inclusion, studies had to report data on carriage or infection with laboratory-confirmed antibiotic-resistant organisms in migrant populations. We extracted data from eligible studies and assessed quality using piloted, standardised forms. We did not examine drug resistance in tuberculosis and excluded articles solely reporting on this parameter. We also excluded articles in which migrant status was determined by ethnicity, country of birth of participants' parents, or was not defined, and articles in which data were not disaggregated by migrant status. Outcomes were carriage of or infection with antibiotic-resistant organisms. We used random-effects models to calculate the pooled prevalence of each outcome. The study protocol is registered with PROSPERO, number CRD42016043681. FINDINGS: We identified 2274 articles, of which 23 observational studies reporting on antibiotic resistance in 2319 migrants were included. The pooled prevalence of any AMR carriage or AMR infection in migrants was 25·4% (95% CI 19·1-31·8; I2 =98%), including meticillin-resistant Staphylococcus aureus (7·8%, 4·8-10·7; I2 =92%) and antibiotic-resistant Gram-negative bacteria (27·2%, 17·6-36·8; I2 =94%). The pooled prevalence of any AMR carriage or infection was higher in refugees and asylum seekers (33·0%, 18·3-47·6; I2 =98%) than in other migrant groups (6·6%, 1·8-11·3; I2 =92%). The pooled prevalence of antibiotic-resistant organisms was slightly higher in high-migrant community settings (33·1%, 11·1-55·1; I2 =96%) than in migrants in hospitals (24·3%, 16·1-32·6; I2 =98%). We did not find evidence of high rates of transmission of AMR from migrant to host populations. INTERPRETATION: Migrants are exposed to conditions favouring the emergence of drug resistance during transit and in host countries in Europe. Increased antibiotic resistance among refugees and asylum seekers and in high-migrant community settings (such as refugee camps and detention facilities) highlights the need for improved living conditions, access to health care, and initiatives to facilitate detection of and appropriate high-quality treatment for antibiotic-resistant infections during transit and in host countries. Protocols for the prevention and control of infection and for antibiotic surveillance need to be integrated in all aspects of health care, which should be accessible for all migrant groups, and should target determinants of AMR before, during, and after migration. FUNDING: UK National Institute for Health Research Imperial Biomedical Research Centre, Imperial College Healthcare Charity, the Wellcome Trust, and UK National Institute for Health Research Health Protection Research Unit in Healthcare-associated Infections and Antimictobial Resistance at Imperial College London

Population structure and evolutionary history of the greater cane rat (Thryonomys swinderianus) from the Guinean Forests of West Africa

Grasscutter (Thryonomys swinderianus) is a large-body old world rodent found in sub-Saharan Africa. The body size and the unique taste of the meat of this major crop pest have made it a target of intense hunting and a potential consideration as a micro-livestock. However, there is insufficient knowledge on the genetic diversity of its populations across African Guinean forests. Herein, we investigated the genetic diversity, population structures and evolutionary history of seven Nigerian wild grasscutter populations together with individuals from Cameroon, Republic of Benin, and Ghana, using five mitochondrial fragments, including D-loop and cytochrome b (CYTB). D-loop haplotype diversity ranged from 0.571 (± 0.149) in Republic of Benin to 0.921 (± 0.013) in Ghana. Within Nigeria, the haplotype diversity ranged from 0.659 (± 0.059) in Cross River to 0.837 (± 0.075) in Ondo subpopulation. The fixation index (FST), haplotype frequency distribution and analysis of molecular variance revealed varying levels of population structures across populations. No significant signature of population contraction was detected in the grasscutter populations. Evolutionary analyses of CYTB suggests that South African population might have diverged from other populations about 6.1 (2.6–10.18, 95% CI) MYA. Taken together, this study reveals the population status and evolutionary history of grasscutter populations in the region

Surgical site infection after gastrointestinal surgery in high-income, middle-income, and low-income countries: a prospective, international, multicentre cohort study

Background: Surgical site infection (SSI) is one of the most common infections associated with health care, but its importance as a global health priority is not fully understood. We quantified the burden of SSI after gastrointestinal surgery in countries in all parts of the world. Methods: This international, prospective, multicentre cohort study included consecutive patients undergoing elective or emergency gastrointestinal resection within 2-week time periods at any health-care facility in any country. Countries with participating centres were stratified into high-income, middle-income, and low-income groups according to the UN's Human Development Index (HDI). Data variables from the GlobalSurg 1 study and other studies that have been found to affect the likelihood of SSI were entered into risk adjustment models. The primary outcome measure was the 30-day SSI incidence (defined by US Centers for Disease Control and Prevention criteria for superficial and deep incisional SSI). Relationships with explanatory variables were examined using Bayesian multilevel logistic regression models. This trial is registered with ClinicalTrials.gov, number NCT02662231. Findings: Between Jan 4, 2016, and July 31, 2016, 13 265 records were submitted for analysis. 12 539 patients from 343 hospitals in 66 countries were included. 7339 (58·5%) patient were from high-HDI countries (193 hospitals in 30 countries), 3918 (31·2%) patients were from middle-HDI countries (82 hospitals in 18 countries), and 1282 (10·2%) patients were from low-HDI countries (68 hospitals in 18 countries). In total, 1538 (12·3%) patients had SSI within 30 days of surgery. The incidence of SSI varied between countries with high (691 [9·4%] of 7339 patients), middle (549 [14·0%] of 3918 patients), and low (298 [23·2%] of 1282) HDI (p < 0·001). The highest SSI incidence in each HDI group was after dirty surgery (102 [17·8%] of 574 patients in high-HDI countries; 74 [31·4%] of 236 patients in middle-HDI countries; 72 [39·8%] of 181 patients in low-HDI countries). Following risk factor adjustment, patients in low-HDI countries were at greatest risk of SSI (adjusted odds ratio 1·60, 95% credible interval 1·05–2·37; p=0·030). 132 (21·6%) of 610 patients with an SSI and a microbiology culture result had an infection that was resistant to the prophylactic antibiotic used. Resistant infections were detected in 49 (16·6%) of 295 patients in high-HDI countries, in 37 (19·8%) of 187 patients in middle-HDI countries, and in 46 (35·9%) of 128 patients in low-HDI countries (p < 0·001). Interpretation: Countries with a low HDI carry a disproportionately greater burden of SSI than countries with a middle or high HDI and might have higher rates of antibiotic resistance. In view of WHO recommendations on SSI prevention that highlight the absence of high-quality interventional research, urgent, pragmatic, randomised trials based in LMICs are needed to assess measures aiming to reduce this preventable complication

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

Blood pressure control and left ventricular hypertrophy in hypertensive Nigerians

Background : Hypertension is a disease characterized by end-organ complications, leading to high morbidity and mortality in many cases. People with untreated or uncontrolled hypertension often run the risk of developing complications directly associated with the disease. Left ventricular hypertrophy (LVH) has been shown to be a significant risk factor for adverse outcomes both in patients with hypertension and in the general population. We investigated the prevalence and pattern of LVH in a treated hypertensive population at the University College Hospital, Ibadan, Nigeria, using non-hypertensive subjects as control. Design and Setting : A prospective observational study performed at the University College Hospital, Ibadan, Nigeria. Methods : Patients had 6 visits, when at least one blood pressure measurement was recorded for each hypertensive subject and average calculated for systolic blood pressure (SBP) and diastolic blood pressure (DBP) separately. The values obtained were used for stratification of the subjects into controlled and uncontrolled hypertension. Subjects also had echocardiograms to determine their left ventricular mass. Results : LVH was found in 14 (18.2%) of the normotensive group, 40 (20.8%) of the uncontrolled hypertensive group and 14 (24.1%) of the controlled hypertensive group when left ventricular mass (LVM) was indexed to body surface area (BSA). When LVM was indexed to height, left ventricular hypertrophy was found in none of the subjects of the normotensive group, while it was found present in 43 (22.4%) and 14 (24.1%) subjects of the uncontrolled and controlled hypertensive groups, respectively. Significant difference in the prevalence of LVH was detected only when LVM was indexed to height alone. Conclusion : Clinic blood pressure is an ineffective way of assessing BP control. Thus in apparently controlled hypertensive subjects, based on office blood pressure, cardiac structural changes do remain despite antihypertensive therapy. This population is still at risk of cardiovascular events.arrière-plan: l’hypertension est une maladie caractérisée par l’orgue de fi n complications menant à élevé de morbidité et mortalité dans de nombreux cas. Personnes avec l’hypertension non traitée ou non contrôlée souvent risquent de développer complications directement associées à la maladie. Laissé ventriculaire hypertrophie (LVH) a été démontré un facteur de risque signifi catif pour les effets négatifs résultats tant chez les patients atteints de l’hypertension et de la population générale. Nous avons a enquêté sur la prévalence et le modèle de LVH dans un traité hypertendues population au University College Hospital, à l’aide Ibadan, Nigeria non-hypertendues des sujets comme contrôle. conception et la confi guration: A éventuel étude d’observation effectuée à la University College Hospital, Ibadan, Nigeria. méthodes: Patients avaient six visites où au moins un sang mesure de pression a été enregistrée pour chaque sujet hypertendues et moyenne calculés séparément pour SBP et DBP. Les valeurs obtenues ont été utilisées pour stratifi cation des sujets dans l’hypertension contrôlée et incontrôlée. Sujets ont également echocardiograms pour déterminer leur masse ventriculaire gauche. résultats: LVH a été trouvé en 14(18.2%) de la groupe normotensive, 40(20.8%) de groupe de hypertendues non contrôlées et 14(24.1%) de hypertendues contrôlée groupe lorsque quitté masse ventriculaire (LVM) a été indexée à corps surface (BSA). Lorsque LVM a été indexé à hauteur, laissé ventriculaire hypertrophie a été trouvé dans aucun du groupe normotensive, bien qu’il a été constaté présents dans les 43(22.4%) et 14(24.1%) de hypertendues non maîtrisée et contrôlée groupes respectivement. Était de différence signifi cative dans la prévalence de la LVH détectés uniquement lorsque LVM a été indexé à hauteur alone. conclusion: clinique artérielle est un moyen ineffi cace de mesurer le contrôle de BP. Ainsi en sujet hypertendues apparemment contrôlée basée sur la pression artérielle de bureau, des changements structurels cardiaques restent malgré thérapie antihypertensive. Cette population est toujours à risque de maladies cardiovasculaires événements